Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial

被引：0

作者：

Buske, C. ^{[1
]}

Tedeschi, A. ^{[2
]}

Trotman, J. ^{[3
]}

Garcia-Sanz, R. ^{[4
]}

MacDonald, D. ^{[5
]}

Leblond, V ^{[6
]}

Mahe, B. ^{[7
]}

Herbaux, C. ^{[8
]}

Tam, C. S. ^{[9
,10
]}

Palomba, M. L. ^{[11
]}

Matous, J., V ^{[12
]}

Shustik, C. ^{[13
]}

Kastritis, E. ^{[1
]}

Treon, S. P. ^{[14
]}

Li, J. ^{[15
]}

Salman, Z. ^{[15
]}

Graef, T. ^{[15
]}

Dimopoulos, M. A. ^{[16
]}

机构：

[1] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany

[2] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[3] Univ Sydney, Concord Hosp, Concord, Australia

[4] Hosp Univ Salamanca, Salamanca, Spain

[5] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada

[6] UPMC Univ Paris, Hop Pitie Salpetriere, APHP, Dept Hematol, Paris, France

[7] CHU Nantes, Nantes, France

[8] CHRU Lille, Inst Hematolog Tranfus, Lille, France

[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[10] St Vincents Hosp, Melbourne, Vic, Australia

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Colorado Blood Canc Inst, Denver, CO USA

[13] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Montreal, PQ, Canada

[14] Dana Farber Canc Inst, Boston, MA 02115 USA

[15] Pharmacyclics LLC, Sunnyvale, CA USA

[16] Univ Athens, Athens, Greece

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V759

引用

页码：252 / 252

页数：1

共 50 条

[1] Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenstrom's Macroglobulinemia (iNNOVATE)
Palomba, M. Lia
Dimopoulos, Meletios A.
Tedeschi, Alessandra
Trotman, Judith
Garcia-Sanz, Ramon
MacDonald, David
Leblond, Veronique
Mahe, Beatrice
Herbaux, Charles
Tam, Constantine
Matous, Jeffrey V.
Shustik, Chaim
Kastritis, Efstathios
Treon, Steven P.
Li, Jianling
Salman, Zeena
Graef, Thorsten
Buske, Christian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S283 - S283
[2] Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenstrom's macroglobulinemia.
Dimopoulos, Meletios A.
Tedeschi, Alessandra
Trotman, Judith
Garcia-Sanz, Ramon
MacDonald, David
Leblond, Veronique
Mahe, Beatrice
Herbaux, Charles
Tam, Constantine
Palomba, Maria Lia
Matous, Jeffrey
Shustik, Chaim
Kastritis, Efstathios
Treon, Steven P.
Li, Jianling
Salman, Zeena
Graef, Thorsten
Buske, Christian
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
Dimopoulos, M. A.
Tedeschi, A.
Trotman, J.
Garcia-Sanz, R.
Macdonald, D.
Leblond, V.
Mahe, B.
Herbaux, C.
Tam, C.
Orsucci, L.
Palomba, M. L.
Matous, J. V.
Shustik, C.
Kastritis, E.
Treon, S. P.
Li, J.
Salman, Z.
Graef, T.
Buske, C.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25): : 2399 - 2410
[4] ASPEN: Results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom Macroglobulinemia (WM)
Buske, C.
Dimopoulos, M.
Opat, S.
D'Sa, S.
Jurczak, W.
Lee, H-P
Cull, G.
Owen, R. G.
Marlton, P.
Wahlin, B. E.
Garcia, Sanz R.
McCarthy, H.
Mulligan, S.
Tedeschi, A.
Castillo, J.
Czyz, J.
Fernandez De Larrea, C.
Belada, D.
Libby, E.
Matous, J.
Motta, M.
Siddiqi, T.
Tani, M.
Trneny, M.
Minnema, M.
Leblond, V
Chan, W. Y.
Schneider, J.
Cohen, A.
Huang, J.
Tam, C. S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 107 - 108
[5] ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM)
Tedeschi, A.
Dimopoulos, M.
Opat, S.
D'Sa, S.
Jurczak, W.
Lee, H.
Cull, G.
Owen, R.
Marlton, P.
Wahlin, B.
Garcia Sanz, R.
McCarthy, H.
Mulligan, S.
Castillo, J.
Czyz, J.
Fernandez De Larrea, C.
Belada, D.
Libby, E.
Matous, J.
Motta, M.
Siddiqi, T.
Tani, M.
Trneny, M.
Minnema, M.
Buske, C.
Leblond, V.
Chan, W.
Schneider, J.
Cohen, A.
Huang, J.
Tam, C.
HAEMATOLOGICA, 2021, 106 (10) : 9 - 10
[6] Ibrutinib and Rituximab in Waldenstrom's Macroglobulinemia
Cavazzini, Francesco
Rigolin, Gian Matteo
Cuneo, Antonio
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (20): : 1974 - 1975
[7] Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Buske, Christian
Tedeschi, Alessandra
Trotman, Judith
Garcia-Sanz, Ramon
MacDonald, David
Leblond, Veronique
Mahe, Beatrice
Herbaux, Charles
Matous, Jeffrey V.
Tam, Constantine S.
Heffner, Leonard T.
Varettoni, Marzia
Palomba, M. Lia
Shustik, Chaim
Kastritis, Efstathios
Treon, Steven P.
Ping, Jerry
Hauns, Bernhard
Arango-Hisijara, Israel
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (01) : 52 - +
[8] Ibrutinib and Rituximab in Waldenstrom's Macroglobulinemia REPLY
Dimopoulos, Meletios A.
Salman, Zeena
Buske, Christian
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (20): : 1975 - 1976
[9] ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM).
Tam, Constantine Si Lun
Opat, Stephen
D'Sa, Shirley
Jurczak, Wojciech
Lee, Hui-Peng
Cull, Gavin
Owen, Roger G.
Marlton, Paula
Wahlin, Bjorn E.
Tedeschi, Alessandra
Castillo, Jorge J.
Siddiqi, Tanya
Buske, Christian
Leblond, Veronique
Chan, Wai Y.
Schneider, Jingjing
Ro, Sunhee K.
Cohen, Aileen
Huang, Jane
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Rituximab and ibrutinib in the treatment of Waldenstrom's macroglobulinemia
Grunenberg, Alexander
Buske, Christian
FUTURE ONCOLOGY, 2019, 15 (23) : 2687 - 2697

← 1 2 3 4 5 →